<DOC>
	<DOCNO>NCT02287857</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Domestic Tenofovir Disoproxil Fumarate Tablets Chinese patient hepatitis B , compare Tenofovir Disoproxil Fumarate Tablets Gilead .</brief_summary>
	<brief_title>Efficacy Safety Domestic Tenofovir Tablets Chinese Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>The initial treatment subject diagnose HBeAg positive negative chronic hepatitis B Aged 18 65 year old，male female Patients previously HBsAgpositive last 6months least：HBeAgpositive subject , HBVDNA &gt; 105copies/ml； HBeAgnegative subject , HBVDNA &gt; 104copies/ml . 2 time upper normal limit ( 2 × ULN ) ≤ alanine aminotransferase ( ALT ) ≤ 10 × ULN . Total serum bilirubin ( TBIL ) ≤ 2.5 × ULN . Prothrombin activity ( PTA ) ≥ 60 % prothrombin time prolong normal ≤ 3 second ) . WBC ≥ 3.5 × 109 / L , PLT ≥ 80 × 109 / L , serum albumin ( ALB ) ≥ 35 g / L. Creatinine ( Cr ) ≤ 1× ULN，serum phosphate normal . Patients sign informed consent form compliance good . Patients infected virus HAV , HCV , HEV , HIV etc . Patients cirrhosis liver cancer . Pregnant woman , lactate woman . Patients severe heart , kidney , endocrine hematopoietic system neuropsychiatric disease . Patients metabolic autoimmune disease systemic lupus erythematosus . Patients allergic study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>